Regarding the possibility of an anthracycline-free neoadjuvant chemotherapy regimen, we previously investigated this in the setting of single HER2 blockade with trastuzumab for the treatment of HER2-positive breast cancer (JBCRG-10 study) [29]. This evidence concerns the gene ERBB2 and breast carcinoma.